Influenza Clinical Trial
Official title:
Observer Blind Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Influenza Vaccine GSK576389A With Various Formulations in Adults Aged 65 Years and Above
Verified date | October 2016 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In order to find the formulation leading to a maximal increase of the immune response while maintaining an acceptable safety profile, this study is designed to evaluate the immunogenicity, safety and reactogenicity of the different formulations of GSK Biologicals' influenza vaccine administered in adults aged 65 years and older compared to Fluarix.
Status | Completed |
Enrollment | 2007 |
Est. completion date | June 10, 2008 |
Est. primary completion date | June 10, 2008 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study. - A male or female aged 18-40 years old or 65 years or older at the time of the vaccination. - Written informed consent obtained from the subject. - Free of an acute aggravation of the health status as established by clinical evaluation (medical history and medical history directed examination) before entering into the study. - If the subject is female, she must be of non-childbearing potential or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of the vaccination series. Exclusion Criteria: - Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days prior to vaccination, or planned use during the study period. - Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study. - Planned administration of a vaccine not foreseen by the study protocol during the entire study period. - Planned administration of an influenza vaccine other than the study vaccines during the entire study period. - Vaccination against influenza since January 2007 (with 2007/2008 or 2006/2007 influenza vaccine). - Administration of more than 14 days of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the study vaccine. - Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination - Hypersensitivity to a previous dose of influenza vaccine. - Allergy to any component of the vaccine. - Acute (active) clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality. - Acute disease at the time of enrolment. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e. axillary temperature<37.5ºC (99.5ºF). - Administration of immunoglobulins and/or any blood products within the three months preceding the first administration of the study vaccine or planned administration during the study. - Any medical conditions in which IM injections are contraindicated. - Lactating female or female planning to become pregnant or to discontinue contraceptive precautions |
Country | Name | City | State |
---|---|---|---|
Germany | GSK Investigational Site | Augsburg | Bayern |
Germany | GSK Investigational Site | Berlin | |
Germany | GSK Investigational Site | Berlin | |
Germany | GSK Investigational Site | Berlin | |
Germany | GSK Investigational Site | Berlin | |
Germany | GSK Investigational Site | Dresden | Sachsen |
Germany | GSK Investigational Site | Essen | Nordrhein-Westfalen |
Germany | GSK Investigational Site | Freital | Sachsen |
Germany | GSK Investigational Site | Gueglingen | Baden-Wuerttemberg |
Germany | GSK Investigational Site | Hamburg | |
Germany | GSK Investigational Site | Hamburg | |
Germany | GSK Investigational Site | Koeln | Nordrhein-Westfalen |
Germany | GSK Investigational Site | Leipzig | Sachsen |
Germany | GSK Investigational Site | Magdeburg | Sachsen-Anhalt |
Germany | GSK Investigational Site | Mainz | Rheinland-Pfalz |
Germany | GSK Investigational Site | Mannheim | Baden-Wuerttemberg |
Germany | GSK Investigational Site | Rhaunen | Rheinland-Pfalz |
Germany | GSK Investigational Site | Rudersberg | Baden-Wuerttemberg |
Germany | GSK Investigational Site | Weinheim | Baden-Wuerttemberg |
Germany | GSK Investigational Site | Wolmirstedt | Sachsen-Anhalt |
Netherlands | GSK Investigational Site | Rotterdam | |
Netherlands | GSK Investigational Site | Rotterdam | |
Sweden | GSK Investigational Site | Eskilstuna | |
Sweden | GSK Investigational Site | Karlskrona | |
Sweden | GSK Investigational Site | Uppsala | |
United Kingdom | GSK Investigational Site | Buckshaw Village, Chorley | Lancashire |
United Kingdom | GSK Investigational Site | Clydebank, Glasgow | |
United Kingdom | GSK Investigational Site | Edgbaston, Birmingham | |
United Kingdom | GSK Investigational Site | Reading | Berkshire |
United Kingdom | GSK Investigational Site | Waterloo, Liverpool |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
Germany, Netherlands, Sweden, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Haemagglutination Inhibition (HI) Antibody Titers | Antibody titers were expressed as Geometric mean titers (GMTs) against each of the 3 vaccine strains in greater than or equal to 65 years age groups only. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. | At Day 21 | |
Secondary | HI Antibody Titers at Day 0 and Day 21 | Antibody titers were expressed as GMTs in all the vaccine groups. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. | At Day 0 and 21 | |
Secondary | HI Antibody Titers at Day 180 | Antibody titers were expressed as GMTs in all the vaccine groups. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. | At Day 180 | |
Secondary | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. | At Day 21 | |
Secondary | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. | At Day 180 | |
Secondary | HI Antibody Seroconversion Factors at Day 21 | Seroconversion factors were defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. | At Day 21 | |
Secondary | HI Antibody Seroconversion Factors at Day 180 | Seroconversion factors were defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. | At Day 180 | |
Secondary | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. | At Day 0 and 21 | |
Secondary | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. | At Day 180 | |
Secondary | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | The markers assessed were Cluster of Differentiation 4-All doubles i.e. CD4-All doubles, CD4-CD40Ligand(L), CD4-interferon gamma (CD4-IFN?), CD4-interleukin 2 (CD4-IL2) and CD4-tumor necrosis factor alpha (CD4-TNFa). The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. | At Days 0 and 21 | |
Secondary | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | The markers assessed were CD4-All doubles, CD4-CD40L, CD4-IFN?, CD4-IL2 and CD4-TNFa. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. | At Day 180 | |
Secondary | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | The markers assessed were Cluster of Differentiation 8-All doubles i.e. CD8-All doubles, CD8-CD40L, CD8-IFN?, CD8-IL2 and CD8-TNFa. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. | At Days 0 and 21 | |
Secondary | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | The markers assessed were CD8-All doubles, CD8-CD40L, CD8-IFN?, CD8-IL2 and CD8-TNFa. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. | At Day 180 | |
Secondary | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 ecchymosis, pain, redness and swelling was greater than 100 millimeter (mm) i.e. > 100 mm and grade 3 pain was considerable pain at rest that prevented normal everyday activities. Any was occurrence of any local symptom regardless of their intensity grade. Any for ecchymosis, redness and swelling was >20mm. | During a 7-day follow-up period (Day 0-6) after vaccination | |
Secondary | Duration of Solicited Local AEs | Duration was defined as number of days with any grade of local symptoms. | During a 7-day follow-up period (Day 0-6) after vaccination | |
Secondary | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any Fever was defined as axillary temperature greater than or equal to 38.0 degree centigrade i.e.= 38.0°C, grade 3 fever was axillary temperature >40°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as a general symptom that prevented normal activity. Related was a general symptom assessed by the investigator as causally related to the study vaccination. | During a 7-day follow-up period (Day 0-6) after vaccination | |
Secondary | Duration of Solicited General AEs | Duration was defined as number of days with any grade of general symptoms. | During a 7-day follow-up period (Day 0-6) after vaccination | |
Secondary | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination. Grade 3 was an event that prevented normal activities and related was defined as an unsolicited AE assessed by the investigator to be causally related to the study vaccination. | During a 21-day follow-up period (Day 0-20) after vaccination | |
Secondary | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as a symptom that prevented normal activity. Related was a symptom assessed by the investigator as causally related to the study vaccination. | Between Day 0 and Day 20 after vaccination | |
Secondary | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as a symptom that prevented normal activity. Related was a symptom assessed by the investigator as causally related to the study vaccination. | Between Day 21 and Day 179 after vaccination | |
Secondary | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 and Day 20 | SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination. | Between Day 0 and Day 20 after vaccination | |
Secondary | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 and Day 179 | SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination. | Between Day 21 and Day 179 after vaccination |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |